13F

Investor

STEMPOINT CAPITAL LP

CIK 0001952142 · filed 2026-05-18 · SEC filing

13F book

$522.3M

Positions

70

32 new · 37 sold

Largest name

9.7%

Scholar Rock Hldg Corp

Est. mark

$7.43M

Price effect on 38 names still held. Flow −$69.9M.
NameTickerSharesValueWeightEst. markChange
Scholar Rock Hldg Corp1.04M$50.9M9.7%$4.53MAdded$11.8M
Abivax Sa313.8K$34.9M6.7%−$7.38MCut−$17.9M
Syndax Pharmaceuticals IncSNDX1.22M$28.4M5.4%$2.86MCut$259.4K
Revolution Medicines Inc281.6K$27.4M5.2%$1.09MAdded$22.4M
Immunovant, Inc.IMVT746.5K$18.5M3.5%−$374.1KAdded$2.15M
Praxis Precision Medicines I56.3K$18.1M3.5%$578.3KAdded$11.9M
MBX Biosciences, Inc.MBX499.5K$14.9M2.9%−$132.8KAdded$12.4M
Mineralys Therapeutics, Inc.MLYS533.4K$14.4M2.8%−$2.67MAdded$3.92M
Enliven Therapeutics, Inc.ELVN363.4K$14.2M2.7%New
CG Oncology, Inc.CGON205.6K$13.9M2.7%New
Biohaven Ltd.BHVN1.59M$13.5M2.6%New
Surrozen Inc525.6K$13.5M2.6%$2.71MCut$788.9K
Roivant Sciences Ltd.ROIV385.8K$10.7M2.0%$2.31MCut−$10.3M
EyePoint, Inc.EYPT810.8K$10.5M2.0%−$1.9MAdded$3.99M
Arcutis Biotherapeutics, Inc.ARQT413.8K$9.75M1.9%−$1.23MAdded$3.22M
Structure Therapeutics Inc.GPCR200.3K$9.65M1.8%−$4.28MCut−$14.8M
Amylyx Pharmaceuticals, Inc.AMLX669.7K$9.31M1.8%$1.03MAdded$2.48M
Dyne Therapeutics, Inc.DYN506.1K$9.18M1.8%−$723.7KCut−$7.16M
Edgewise Therapeutics, Inc.EWTX290.9K$9.16M1.8%$1.94MCut$207.1K
Cytokinetics IncCYTK129.6K$8.54M1.6%$307.1KCut−$798.6K
Spyre Therapeutics, Inc.SYRE167.6K$8.45M1.6%$572.4KAdded$7.39M
Denali Therapeutics Inc.DNLI426.6K$8.19M1.6%$1.13MAdded$1.27M
Xenon Pharmaceuticals Inc.XENE140.8K$8.18M1.6%$1.88MCut−$7.44M
Celldex Therapeutics Inc New254.3K$8.07M1.5%New
Protagonist Therapeutics, IncPTGX72.6K$7.65M1.5%$1.07MAdded$2.46M
Tyra Biosciences, Inc.TYRA193.2K$7.4M1.4%New
Dianthus Therapeutics Inc85.5K$7.18M1.4%$3.39MAdded$3.91M
Celcuity Inc.CELC60.1K$6.86M1.3%$864.9KCut−$4.95M
Definium TherapeDFTX325.5K$6.15M1.2%New
BioAge Labs, Inc.BIOA338.7K$5.92M1.1%New
Newamsterdam Pharma Company180.7K$5.78M1.1%−$224.4KAdded$3.22M
Acadia Pharmaceuticals IncACAD242.6K$5.4M1.0%New
Assembly Biosciences, Inc.ASMB185.4K$5.15M1.0%−$981.1KAdded−$184.5K
Alumis Inc.ALMS229.6K$5.06M1.0%New
Nurix Therapeutics, Inc.NRIX315.2K$4.89M0.9%New
Zura Bio LtdZURA753.5K$4.48M0.9%New
Evommune, Inc.EVMN193.8K$4.39M0.8%$375.8KAdded$3.22M
Tango Therapeutics, Inc.TNGX200.9K$4.2M0.8%New
Sensei Biotherapeutics IncFTH132.9K$4.19M0.8%New
Relmada Therapeutics, Inc.RLMD597.4K$4.16M0.8%New
Erasca, Inc.ERAS239.9K$3.88M0.7%New
Johnson & JohnsonJNJ15.4K$3.77M0.7%$577.9KCut−$3.48M
X4 Pharmaceuticals, IncXFOR850.7K$3.51M0.7%$110.6KCut−$80.3K
Vaxcyte, Inc.PCVX59.1K$3.43M0.7%New
Whitehawk Therapeutics, Inc.WHWK939.4K$3.24M0.6%$967.5KCut−$289.5K
Helix Acquisition Corp. IIIHLXC305K$3.1M0.6%New
Tenax Therapeutics, Inc.TENX188.7K$3.02M0.6%New
Alkermes plc.ALKS80.5K$2.85M0.5%New
Pharvaris N.V.PHVS86.6K$2.45M0.5%$29.2KAdded$827.2K
Invivyd, Inc.IVVD1.87M$2.44M0.5%−$1.16MAdded−$7.95K
Jade Biosciences, Inc.JBIO154K$2.16M0.4%New
Twist Bioscience CorpTWST43.1K$2.05M0.4%$681.1KCut−$14.4M
MapLight Therapeutics, Inc.MPLT100K$2.03M0.4%$276.5KHeld
Avalo Therapeutics, Inc.AVTX134.7K$2.01M0.4%−$435.2KCut−$449.9K
Ionis Pharmaceuticals IncIONS26.4K$1.98M0.4%New
Immunocore Hldgs Plc63.5K$1.92M0.4%New
Forte Biosciences, Inc.FBRX58K$1.5M0.3%New
Sionna Therapeutics, Inc.SION36.5K$1.46M0.3%New
Sab Biotherapeutics Inc375K$1.44M0.3%$13.2KAdded$888.1K
Solid Biosciences Inc.SLDB195.4K$1.41M0.3%New
Lipocine Inc New160.4K$1.28M0.2%New
Uniqure Nv78.1K$1.28M0.2%−$329.6KAdded$235.8K
Lb Pharmaceuticals IncLBRX50K$1.23M0.2%New
C4 Therapeutics, Inc.CCCC453.2K$1.19M0.2%New
Edwards Lifesciences CorpEW14.6K$1.17M0.2%New
Capricor Therapeutics, Inc.CAPR37.6K$1.14M0.2%$27.5KAdded$627.6K
Biodesix IncBDSX70K$1.02M0.2%New
Sutro Biopharma, Inc.STRO23.3K$580.3K0.1%New
Spruce Biosciences, Inc.SPRB6.36K$415.6K0.1%New
Vistagen Therapeutics, Inc.VTGN616.7K$58.2K0.0%−$83.9KHeld

Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.